🇺🇸 FDA
Patent

US 11958908

Compositions and methods for the depletion of CD117+ cells

granted A61KA61K2035/124A61K2039/505

Quick answer

US patent 11958908 (Compositions and methods for the depletion of CD117+ cells) held by CRISPR THERAPEUTICS AG expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CRISPR THERAPEUTICS AG
Grant date
Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K2035/124, A61K2039/505, A61K35/545, A61K38/00